Goldman Sachs has missed two of the biggest acquisitions of the year. The bank didnt take part in the $23 billion merger of Heinz Co. by Brazilian investment firm 3G capital and Warren Buffetts Berkshire Hathaway Inc. announced in February.
The company also worked with private-equity firms in an attempt to seal a deal with the equipment maker Life Technologies Corp. Specialists stated that company preferred to be bought for $13.6 billion by Thermo Fisher Scientific Inc. in the largest healthcare deal this year leaving Goldman Sachs out of the money.
Recent months have been hard for finding a great deal for Goldman as the company failed to put together three potential mergers in the healthcare industry. However, Goldman succeeded to come up with a deal out of nowhere. Valeant Pharmaceuticals International Inc. $8.7 billion acquisition of contact lens maker Bausch and Lomb Holdings Inc. was announced this week.
Goldman Sachs took a role of a financial moderator between the two sides and its being said that company is expecting as much as $35 million in advisory fees along with $140 million in financing fees. The bank is arranging debt financing to Valeant while serving as lead advisor to Bausch & Lomb according to its own statements on May 27.
The financial institution leads the sector for number of deals made so far, while trailing by money volume according to data compiled by Bloomberg. Till date Goldman Sachs has completed 107 deals, compared to 66 of JP Morgan Chase & Co. and only 57 by Bank of America Corp.
On the money volume statistic things look differently as Bank of America leads with $171 billion followed by JP Morgans 149 billion and Goldman Sachs has advised for $140 billion.
Yesterday company reached its best share price year to date which is a rebound from mid Aprils fall triggered by companys inability to sign a large deal.
TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover 
